Caligan Partners LP Discloses 7.2% Stake in Avalo Therapeutics, Inc. (AVTX)

Caligan Partners LP and its Managing Partner, David Johnson, have filed a Schedule 13G/A disclosing a 7.2% ownership stake in Avalo Therapeutics, Inc. (AVTX). As of the event date on March 31, 2026, the reporting persons beneficially own 1,635,023 shares of Common Stock. This position represents an increase from the previously reported 0.0% ownership, indicating a new significant holding by the investment manager. Caligan Partners LP serves as the investment manager to various funds and accounts that hold these shares. The filing specifies that the shares were acquired in the ordinary course of business and are not held for the purpose of changing or influencing the control of the issuer. The ownership percentage is based on 22,788,452 shares of Common Stock outstanding as of March 18, 2026. The reporting persons share voting and dispositive power over the entire reported amount.